Literature DB >> 15794077

Morphology and distribution of nasal telangiectasia in HHT-patients with epistaxis.

Benedikt J Folz1, Ana Cerra Wollstein, Burkard M Lippert, Jochen A Werner.   

Abstract

BACKGROUND: Epistaxis in hereditary hemorrhagic telangiectasia (HHT; Rendu-Osler-Weber syndrome) is a frequent symptom that may be caused by a multitude of different genetic and epigenetic phenomena. This investigation analyzes the distribution of nasal telangiectasia in 21 patients with HHT.
METHODS: The patients were examined for endonasal telangiectasia by videoendoscopy with rigid endoscopes; in addition, the anterior portion of the nose was examined under the operating microscope. The endonasal findings were recorded on videotape and then evaluated in the media laboratory.
RESULTS: Morphology of the nasal telangiectasia showed wide variations: the vessels were shaped like spots, loops, or spiders or they clustered and resembled raspberries. Gender did not have an influence on the phenotype of telangiectasia, whereas advancing age correlated with a higher density of telangiectasia. Patients with an intact nasal septum exhibited the bulk of telangiectasia in the anterior nasal cavity but also on the middle turbinates, the floor of the nose, and within the valve area. Patients with septal perforations displayed the majority of telangiectasia around the edge of the perforations, on the floor of the nose, and on the turbinates. Scattered telangiectasia also could be found in the profound parts of the nasal cavity and in the nasopharynx, especially in patients with septal perforations.
CONCLUSION: The shapes of endonasal telangiectasia in HHT patients are very heterogeneous; predilection sites could first of all be found within the anterior portion of the nose. Morphology and distribution of endonasal telangiectasia change as a result of therapeutic interventions, development of septal perforations, and with advancing age. Therefore, repeat endoscopies are recommended to assess the actual stage of the disease before epistaxis therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15794077

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  6 in total

1.  [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

Authors:  C Rohrmeier; T S Kühnel
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

2.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

3.  Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents.

Authors:  Benedikt J Folz; Barbara Zoll; Heiko Alfke; André Toussaint; Rolf F Maier; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-24       Impact factor: 2.503

4.  Classification of endonasal HHT lesions using digital microscopy.

Authors:  F Haubner; A Schneider; H Schinke; M Bertlich; B G Weiss; M Canis; F Kashani
Journal:  Orphanet J Rare Dis       Date:  2021-04-17       Impact factor: 4.123

5.  Hereditary haemorrhagic telangiectasia in a patient taking anticoagulant drugs who has sustained facial trauma.

Authors:  Bartłomiej Kamiński; Katarzyna Błochowiak; Karolina Olek-Hrab; Jerzy Sokalski; Henryk Witmanowski
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837

6.  Rapid hemostasis: a novel and effective outpatient procedure using microwave ablation to control epistaxis of isolated mucosal bulge lesions.

Authors:  Zheng Cai Lou
Journal:  Braz J Otorhinolaryngol       Date:  2019-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.